Real world data collection is difficult. In China, there are additional challenges to overcome. The main obstacles to real world data collection in China revolve around data privacy and data integration and quality. This article highlights below these obstacles, as...
There are several trends emerging to create an ideal oncology market for biopharma companies in China. Below, we’ve highlighted some of the key attributes of the market. The Overall China Oncology Landscape China has the largest number of cancer patients globally: 4...
GenomiCare’s sponsored ISPOR Webinar featured a cast of experts from Novartis, Roche, and AstraZeneca in a engaging discussion about Real World Evidence in China. Key takeaways included: On the data, itself: Representativeness and Quality of data is paramount Overall...
On June 29th, GenomiCare Biotechnology hosted an ISPOR webinar about the opportunities/challenges of RWE/RWD collection from China.
GenomiCare Scientific Advisory Board Member Dr. Chen Lieping is elected by National Academy of Sciences as new member
GenomiCare is proud to announce On April 27, 2021, the National Academy of Sciences (NAS) announced the latest list of newly elected members, including Dr. Chen Lieping, a member of the GenomiCare Scientific Advisory Board (SAB).
The 2020 China Technology Fast 50 & China Rising Star lists were officially published by the Beijing office of Deloitte on December 9 and reported by dozens of news outlets. GenomiCare is on list of the 2020 China Rising Star thanks to its “two-wheel-drive” business model, powerful translational cancer research, and flexible data solutions for clinical oncology drug development.
GenomiCare is proud to announce that it has won the 2020 Leading Sci-Tech Innovation Company Award for its innovations in the R&D of cancer precision medicine, and that Dr. Xu Qiang, the company’s founder and CEO, has been named a 2020 Sci-Tech Innovation Leader.
GenomiCare, Inc. has recently reached a cooperation agreement with AWS on HIPAA compliance. This enables GenomiCare to store, process and utilize masked clinical data in a safer environment and therefore ensures the security and availability of personal health information (PHI) for our clients all over the world.
GenomiCare unveiled the results of PD-L1 immunohistochemistry images in outcome prediction at ASCO 2020
Recently, the summary of the results of GenomiCare PD-L1 immunohistochemistry (IHC) images in outcome prediction was included in the ASCO 2020 (56th Annual Meeting of the American Society of Clinical Oncology), entitled “Application of Automated Segmentation and Classification of PD-L1 Immunohistochemistry Images in Cancer Treatment Prediction”.